ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 1648

Increasing Rates of Positivity of Autoantibodies Indicates a Shorter Time-to-Diagnosis of Future Rheumatoid Arthritis

Dylan Bergstedt1, Ryan Peterson2, Marie Feser1, LauraKay Moss1, Geoffrey Thiele3, Ted Mikuls3, Jess Edison4, V. Michael Holers1 and Kevin Deane5, 1University of Colorado Denver, Aurora, CO, 2Colorado School of Public Health, Aurora, CO, 3University of Nebraska Medical Center, Omaha, NE, 4Walter Reed National Military Medical Center, Bethesda, MD, 5University of Colorado Denver, Denver, CO

Meeting: ACR Convergence 2021

Keywords: Anti-citrullinated Protein Autoantibodies (ACPAs), Preclinical Rheumatoid Arthritis, PREDICTION, Rheumatoid Factor

  • Tweet
  • Email
  • Print
Session Information

Date: Tuesday, November 9, 2021

Session Title: RA – Diagnosis, Manifestations, & Outcomes Poster IV: Outcomes, Trajectory of Disease, & Epidemiology (1645–1673)

Session Type: Poster Session D

Session Time: 8:30AM-10:30AM

Background/Purpose: Rheumatoid arthritis (RA) has a ‘pre-RA’ period that can be defined by elevations in autoantibodies to citrullinated protein antigens (ACPA) and rheumatoid factor (RF) prior to clinically-apparent inflammatory arthritis. ACPA and RF elevations can be used to predict future RA; however, most models of prediction have only used autoantibody data from a single time point. To address this gap, we evaluated changing autoantibody positivity and timing of future RA in a sample set of pre- and post-RA samples from the Department of Defense Serum Repository.

Methods: We evaluated serial pre- and post-RA diagnosis serum samples from a cohort of 215 individuals with RA (213 with RA classified by 1987 criteria; 2 cases by diagnosis by a board-certified rheumatologist). All samples were tested for ACPA using the CCP3 assay (Inova, positivity based on manufacturer’s recommendation) and RF-IgM, IgA and IgG (Inova, positivity based on level present in < 2% of healthy controls) We stratified cases by sex and utilized a Cox regression model that assumed a Markov renewal process to estimate the hazard of developing RA based on concurrent positivity of autoantibodies within individuals over time.

Results: Descriptive characteristics of the cases are presented in the Table. Overall, women were more likely than men to be positive for any RF pre- and post-RA diagnosis. Within cases stratified by gender, an increasing number of positive autoantibodies was associated with a shorter time to diagnosis of RA (Figure). In particular, positivity for CCP3 and any RF indicated a median time-to-diagnosis of RA of 1.52 years in men, and 1.08 years in women. Notably, if an individual’s autoantibody positivity increased, their hazard of developing RA would increase (i.e. their time to diagnosis would update to a new estimate) (Figure).

Conclusion: In this pre-RA cohort, prevalence of positivity of a combination of CCP3 and RF occur closer to diagnosis. This suggests an expansion of autoimmunity across the development of RA where biologic processes influencing both ACPA and RF production culminate in the transition to clinically-apparent RA. Furthermore, while predictive ability herein is limited given the retrospective design of this project, prior work has established that autoantibody positivity, especially ACPA positivity, is predictive for future RA (reviewed in Deane Arthritis Rheum 2021). As such, if these findings are further validated, they could be applied in a 2-step fashion to identify an individual’s overall risk for future RA, then evaluate the changing positivity of autoantibodies over time to estimate their evolving risk and timing of future RA. Notably, the literature regarding the rate of autoantibody positivity in RA in men and women is conflicting, and issues such as diagnostic bias can influence these findings; however, the gender differences seen herein in the prevalence of autoantibody positivity and prediction of timing of future RA needs further investigation. Finally, while additional study is needed, these findings also suggest that in clinical trials for RA prevention altering the development of new autoantibodies may be a measure to understand success of an intervention.

Slide1.jpeg”Table

Slide2.jpeg”Figure


Disclosures: D. Bergstedt, None; R. Peterson, None; M. Feser, None; L. Moss, None; G. Thiele, Regeneron, 6; T. Mikuls, Gilead Sciences, 2, Horizon, 2, 5, Pfizer Inc, 2, Sanofi, 2, Bristol-Myers Squibb, 2; J. Edison, None; V. Holers, None; K. Deane, Inova Diagnostics, Inc, 5, Bristol Meyers Squibb, 1, 5, Janssen Research and Development, LLC, 5, imaware, 2, ThermoFisher, 2, 5, Medscape, 6.

To cite this abstract in AMA style:

Bergstedt D, Peterson R, Feser M, Moss L, Thiele G, Mikuls T, Edison J, Holers V, Deane K. Increasing Rates of Positivity of Autoantibodies Indicates a Shorter Time-to-Diagnosis of Future Rheumatoid Arthritis [abstract]. Arthritis Rheumatol. 2021; 73 (suppl 9). https://acrabstracts.org/abstract/increasing-rates-of-positivity-of-autoantibodies-indicates-a-shorter-time-to-diagnosis-of-future-rheumatoid-arthritis/. Accessed January 30, 2023.
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2021

ACR Meeting Abstracts - https://acrabstracts.org/abstract/increasing-rates-of-positivity-of-autoantibodies-indicates-a-shorter-time-to-diagnosis-of-future-rheumatoid-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2023 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences